Skip to content

Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease

By Avolio, Salvatore; Summa, Vincenzo
From Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2010), 10(14), 1403-1422. Language: English, Database: CAPLUS, DOI:10.2174/156802610792232051

Hepatitis C virus (HCV) is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). No vaccine is currently available to prevent hepatitis C, and the current std. of care (SOC) – pegylated interferon-α (PEG-IFN-α) in combination with ribavirin (RBV) – is only partially effective and it also presents side effects. Novel treatment options now under intensive development are focused on the discovery of inhibitors of HCV-specific enzymes. The HCV NS3 protease plays an essential role for viral replication and it is recognized as one of the most attractive targets for developing novel anti-HCV therapies. After two decades of research efforts a no. of potent active-site inhibitors of the NS3 protease have been generated and some of them are in late stage of clin. trials. A particularly interesting class of HCV NS3 protease inhibitors are based on depeptidized macrocyclic structures. The article reviews the recent progresses made in the discovery and development of macrocyclic inhibitors of the HCV NS3 protease as described in the most recent scientific literature (patent excluded), from a medicinal chem. perspective.

More info on




Back To Top